InsidersTradesSigma
Follow the Prelude Therapeutics Inc share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Prelude Therapeutics Inc has recorded 55 insider filings. Market capitalisation: €312.6m. The latest transaction was filed on 28 April 2026 (J). Among the most active insiders: Huang Jane. Every trade is free.
55
Insider Decl.
n/a
Thresholds
€32m
24 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Prelude Therapeutics Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$8.00.
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 April 2026
Declarations55 total
1,407,000 sharesCommon StockSEC:0001231919-26-000422:0
1,689,189 shares@ US$4.441.84% mcap41.8% of flowCommon StockSEC:0000947871-26-000462:0
Canonical exit: 20 Jul 2026 (T+90)
1,126,126 shares@ US$4.441.23% mcap27.9% of flowCommon StockSEC:0000947871-26-000462:1
Canonical exit: 20 Jul 2026 (T+90)
1,689,189 shares@ US$4.441.84% mcap41.8% of flowCommon StockSEC:0000947871-26-000461:0
Canonical exit: 20 Jul 2026 (T+90)
1,126,126 shares@ US$4.441.23% mcap27.9% of flowCommon StockSEC:0000947871-26-000461:1
Canonical exit: 20 Jul 2026 (T+90)
9,375 sharesCommon StockSEC:0001683913-25-000004:0
9,375 sharesCommon StockSEC:0001562180-25-005346:0
9,375 sharesCommon StockSEC:0001562180-25-003036:0
100,000 shares@ US$0.692529.8% of flowCommon StockSEC:0001562180-25-002779:0
Canonical exit: 23 Jun 2025 (T+90)
675,000 shares@ US$0.692546.8% of flowCommon StockSEC:0001562180-25-002778:0
Canonical exit: 23 Jun 2025 (T+90)
5,416 shares@ US$0.72940.4% of flowCommon StockSEC:0001562180-25-002697:0
Canonical exit: 18 Jun 2025 (T+90)
29,999 shares@ US$0.75442.3% of flowCommon StockSEC:0001562180-25-002541:0
Canonical exit: 12 Jun 2025 (T+90)
47,500 shares@ US$0.71043.3% of flowCommon StockSEC:0001562180-25-002392:0
Canonical exit: 10 Jun 2025 (T+90)
9,375 sharesCommon StockSEC:0001562180-25-000237:0
5,000 shares@ US$1.20870.6% of flowCommon StockSEC:0001562180-25-000031:0
Canonical exit: 31 Mar 2025 (T+90)
10,000 shares@ US$1.201.2% of flowCommon StockSEC:0001562180-25-000008:0
Canonical exit: 30 Mar 2025 (T+90)
3,075 shares@ US$1.151.6% of flowCommon StockSEC:0001562180-24-008565:0
Canonical exit: 20 Mar 2025 (T+90)
25,000 shares@ US$0.905564.5% of flowCommon StockSEC:0001562180-24-008532:0
Canonical exit: 19 Mar 2025 (T+90)
100,000 shares@ US$0.93219.6% of flowCommon StockSEC:0001562180-24-008531:0
Canonical exit: 18 Mar 2025 (T+90)
9,375 sharesCommon StockSEC:0001562180-24-007253:0
9,375 sharesCommon StockSEC:0001562180-24-005641:0
9,375 sharesCommon StockSEC:0001562180-24-003347:0
9,375 sharesCommon StockSEC:0001562180-24-000338:0
9,375 sharesCommon StockSEC:0001562180-23-007230:0
9,375 sharesCommon StockSEC:0001209191-23-041553:0
25 of 55 declarations
关于 Prelude Therapeutics Inc
Prelude Therapeutics Inc. (NASDAQ: PRLD) 是一家在美国特拉华州威尔明顿设有总部的美国上市生物制药公司。公司成立于2016年，围绕一个明确的理念建立：为高度未满足医疗需求的领域开发精准肿瘤药物。其投资案例是一家早期生物技术公司，其价值创造取决于科学执行、临床数据生成以及与大型制药公司建立战略伙伴关系的潜力。 Prelude的核心业务是发现和开发新型癌症疗法。公司的产品线日益专注于差异化生物学，特别是高选择性KAT6A降解剂和突变选择性JAK2V617F抑制剂。实际上，Prelude正在针对临床验证的通路，采用可能更精确的作用机制，旨在改善难治性癌症的疗效和安全性之间的平衡。公司还致力于其他肿瘤项目，但其近期战略表明对最有前景的资产进行了更明确的优先排序。 从竞争角度来看，Prelude在一个拥挤且高度创新的肿瘤领域运营。其竞争优势不是规模，而是专业化：一个专注的科学平台、新颖的机制以及在选定适应症中创造同类首创或同类最佳疗法的可能性。与许多小型生物技术公司一样，该股票高度依赖即将到来的里程碑，包括监管备案、首次人体研究、早期临床试验结果以及公司维持充足资金的能力。这使得PRLD成为一个经典的、高风险/高回报的开发阶段生物技术故事。 近期公司发展至关重要。2025年11月，Prelude宣布与Incyte达成一项期权协议，该协议围绕其此前未披露的JAK2V617F突变选择性抑制剂项目，同时优先开发其同类首创的KAT6A选择性降解剂，并暂停某些SMARCA2项目。2026年初，公司表示其KAT6A项目仍按计划在2026年中期提交IND申请，并于2026年下半年启动1期临床。Prelude还在2026年完成了股权融资，这突显了生物技术开发对资本的密集需求以及公司为推进产品线而持续融资的需求。 对于法国、比利时和瑞士的投资者来说，Prelude Therapeutics最好被视为一家在美国纳斯达克上市的专业肿瘤研究公司，具有显著的科学选择性，但也伴随着巨大的临床、监管和融资风险。
